Human Molecular Genetics, 2003, Vol. 12, No. 13 1555-1567
DOI: 10.1093/hmg/ddg169
© 2003 Oxford University Press
Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease
1Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada V5Z 4H4, 2Department of Neurology, Emory University, Atlanta, GA 30322, USA and 3Department of Human Genetics, Emory University, Atlanta, GA 30322, USA
Received March 4, 2003; Accepted May 5, 2003
An expanded CAG repeat is the underlying genetic defect in Huntington disease, a disorder characterized by motor, psychiatric and cognitive deficits and striatal atrophy associated with neuronal loss. An accurate animal model of this disease is crucial for elucidation of the underlying natural history of the illness and also for testing experimental therapeutics. We established a new yeast artificial chromosome (YAC) mouse model of HD with the entire human HD gene containing 128 CAG repeats (YAC128) which develops motor abnormalities and age-dependent brain atrophy including cortical and striatal atrophy associated with striatal neuronal loss. YAC128 mice exhibit initial hyperactivity, followed by the onset of a motor deficit and finally hypokinesis. The motor deficit in the YAC128 mice is highly correlated with striatal neuronal loss, providing a structural correlate for the behavioral changes. The natural history of HD-related changes in the YAC128 mice has been defined, demonstrating the presence of huntingtin inclusions after the onset of behavior and neuropathological changes. The HD-related phenotypes of the YAC128 mice show phenotypic uniformity with low inter-animal variability present, which together with the age-dependent striatal neurodegeneration make it an ideal mouse model for the assessment of neuroprotective and other therapeutic interventions.
* To whom correspondence should be addressed at: Centre for Molecular Medicine and Therapeutics, 980 West 28th Avenue, Vancouver, BC, Canada V5Z 4H4. Tel: +1 6048753535; Fax: +1 6048753819; Email: mrh{at}cmmt.ubc.ca
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  F. J. Bode, M. Stephan, H. Suhling, R. Pabst, R. H. Straub, K. A. Raber, M. Bonin, H. P. Nguyen, O. Riess, A. Bauer, et al. Sex differences in a transgenic rat model of Huntington's disease: decreased 17{beta}-estradiol levels correlate with reduced numbers of DARPP32+ neurons in males Hum. Mol. Genet., September 1, 2008; 17(17): 2595 - 2609. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-E. Wang, S. Tydlacka, A. L. Orr, S.-H. Yang, R. K. Graham, M. R. Hayden, S. Li, A. W.S. Chan, and X.-J. Li Accumulation of N-terminal mutant huntingtin in mouse and monkey models implicated as a pathogenic mechanism in Huntington's disease Hum. Mol. Genet., September 1, 2008; 17(17): 2738 - 2751. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Bjorkqvist, E. J. Wild, J. Thiele, A. Silvestroni, R. Andre, N. Lahiri, E. Raibon, R. V. Lee, C. L. Benn, D. Soulet, et al. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease J. Exp. Med., August 4, 2008; 205(8): 1869 - 1877. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. C. Warby, C. N. Doty, R. K. Graham, J. B. Carroll, Y.-Z. Yang, R. R. Singaraja, C. M. Overall, and M. R. Hayden Activated caspase-6 and caspase-6-cleaved fragments of huntingtin specifically colocalize in the nucleus Hum. Mol. Genet., August 1, 2008; 17(15): 2390 - 2404. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Gray, D. I. Shirasaki, C. Cepeda, V. M. Andre, B. Wilburn, X.-H. Lu, J. Tao, I. Yamazaki, S.-H. Li, Y. E. Sun, et al. Full-Length Human Mutant Huntingtin with a Stable Polyglutamine Repeat Can Elicit Progressive and Selective Neuropathogenesis in BACHD Mice J. Neurosci., June 11, 2008; 28(24): 6182 - 6195. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Milnerwood and L. A. Raymond Corticostriatal synaptic function in mouse models of Huntington's disease: early effects of huntingtin repeat length and protein load J. Physiol., December 15, 2007; 585(3): 817 - 831. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. B. Fernandes, K. G. Baimbridge, J. Church, M. R. Hayden, and L. A. Raymond Mitochondrial Sensitivity and Altered Calcium Handling Underlie Enhanced NMDA-Induced Apoptosis in YAC128 Model of Huntington's Disease J. Neurosci., December 12, 2007; 27(50): 13614 - 13623. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Valenza, J. B. Carroll, V. Leoni, L. N. Bertram, I. Bjorkhem, R. R. Singaraja, S. Di Donato, D. Lutjohann, M. R. Hayden, and E. Cattaneo Cholesterol biosynthesis pathway is disturbed in YAC128 mice and is modulated by huntingtin mutation Hum. Mol. Genet., September 15, 2007; 16(18): 2187 - 2198. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Y. Heng, S. J. Tallaksen-Greene, P. J. Detloff, and R. L. Albin Longitudinal Evaluation of the Hdh(CAG)150 Knock-In Murine Model of Huntington's Disease J. Neurosci., August 22, 2007; 27(34): 8989 - 8998. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kuhn, D. R. Goldstein, A. Hodges, A. D. Strand, T. Sengstag, C. Kooperberg, K. Becanovic, M. A. Pouladi, K. Sathasivam, J.-H. J. Cha, et al. Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage Hum. Mol. Genet., August 1, 2007; 16(15): 1845 - 1861. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T.-S. Tang, X. Chen, J. Liu, and I. Bezprozvanny Dopaminergic Signaling and Striatal Neurodegeneration in Huntington's Disease J. Neurosci., July 25, 2007; 27(30): 7899 - 7910. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Metzler, L. Gan, T. Pan Wong, L. Liu, J. Helm, L. Liu, J. Georgiou, Y. Wang, N. Bissada, K. Cheng, et al. NMDA Receptor Function and NMDA Receptor-Dependent Phosphorylation of Huntingtin Is Altered by the Endocytic Protein HIP1 J. Neurosci., February 28, 2007; 27(9): 2298 - 2308. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Cyr, T. D. Sotnikova, R. R. Gainetdinov, and M. G. Caron Dopamine enhances motor and neuropathological consequences of polyglutamine expanded huntingtin FASEB J, December 1, 2006; 20(14): 2541 - 2543. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. P. Nguyen, P. Kobbe, H. Rahne, T. Worpel, B. Jager, M. Stephan, R. Pabst, C. Holzmann, O. Riess, H. Korr, et al. Behavioral abnormalities precede neuropathological markers in rats transgenic for Huntington's disease Hum. Mol. Genet., November 1, 2006; 15(21): 3177 - 3194. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. A. Oliveira, S. Chen, S. Almeida, R. Riley, J. Goncalves, C. R. Oliveira, M. R. Hayden, D. G. Nicholls, L. M. Ellerby, and A. C. Rego Mitochondrial-Dependent Ca2+ Handling in Huntington's Disease Striatal Cells: Effect of Histone Deacetylase Inhibitors J. Neurosci., October 25, 2006; 26(43): 11174 - 11186. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Van Raamsdonk, W. T. Gibson, J. Pearson, Z. Murphy, G. Lu, B. R. Leavitt, and M. R. Hayden Body weight is modulated by levels of full-length Huntingtin Hum. Mol. Genet., May 1, 2006; 15(9): 1513 - 1523. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Van Raamsdonk, Z. Murphy, E. J. Slow, B. R. Leavitt, and M. R. Hayden Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease Hum. Mol. Genet., December 15, 2005; 14(24): 3823 - 3835. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J. Slow, R. K. Graham, A. P. Osmand, R. S. Devon, G. Lu, Y. Deng, J. Pearson, K. Vaid, N. Bissada, R. Wetzel, et al. Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions PNAS, August 9, 2005; 102(32): 11402 - 11407. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. C. Warby, E. Y. Chan, M. Metzler, L. Gan, R. R. Singaraja, S. F. Crocker, H. A. Robertson, and M. R. Hayden Huntingtin phosphorylation on serine 421 is significantly reduced in the striatum and by polyglutamine expansion in vivo Hum. Mol. Genet., June 1, 2005; 14(11): 1569 - 1577. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Van Raamsdonk, J. Pearson, D. A. Rogers, N. Bissada, A. W. Vogl, M. R. Hayden, and B. R. Leavitt Loss of wild-type huntingtin influences motor dysfunction and survival in the YAC128 mouse model of Huntington disease Hum. Mol. Genet., May 15, 2005; 14(10): 1379 - 1392. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Van Raamsdonk, J. Pearson, E. J. Slow, S. M. Hossain, B. R. Leavitt, and M. R. Hayden Cognitive Dysfunction Precedes Neuropathology and Motor Abnormalities in the YAC128 Mouse Model of Huntington's Disease J. Neurosci., April 20, 2005; 25(16): 4169 - 4180. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Q. Harper, P. D. Staber, X. He, S. L. Eliason, I. H. Martins, Q. Mao, L. Yang, R. M. Kotin, H. L. Paulson, and B. L. Davidson From the Cover: RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model PNAS, April 19, 2005; 102(16): 5820 - 5825. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T.-S. Tang, E. Slow, V. Lupu, I. G. Stavrovskaya, M. Sugimori, R. Llinas, B. S. Kristal, M. R. Hayden, and I. Bezprozvanny Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease PNAS, February 15, 2005; 102(7): 2602 - 2607. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Canals, J. R. Pineda, J. F. Torres-Peraza, M. Bosch, R. Martin-Ibanez, M. T. Munoz, G. Mengod, P. Ernfors, and J. Alberch Brain-Derived Neurotrophic Factor Regulates the Onset and Severity of Motor Dysfunction Associated with Enkephalinergic Neuronal Degeneration in Huntington's Disease J. Neurosci., September 1, 2004; 24(35): 7727 - 7739. [Abstract] [Full Text] [PDF]
|
|